Qsam Biosciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Qsam Biosciences Inc (APGR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Qsam Biosciences Inc vs Its Competitors
- Peer differentiation: Revenue per employee of $0.00M compares with $0.02M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Qsam Biosciences Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Qsam Biosciences Inc | - | - | - | No |
| Competitors combined (3) | - | - | - | |
| High-Confidence Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
APGR Stock Performance relative to its Competitors
APGR Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Actinium Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Qsam Biosciences Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Qsam Biosciences Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Qsam Biosciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Qsam Biosciences Inc | - | 0.00 |
| Fusion Pharmaceuticals Inc | 1,805.37 | 0.90 |
| Rayzebio Inc | 962.34 | - |
| Actinium Pharmaceuticals Inc | 35.18 | 1.46 |
| SUBTOTAL | 2,802.88 | 2.37 |
Sources: Qsam Biosciences Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Qsam Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Qsam Biosciences Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Fusion Pharmaceuticals Inc. | Named by the company | 85% |
| RayzeBio, Inc. | Named by the company | 85% |
| Actinium Pharmaceuticals, Inc. | Named by the company | 85% |
| Q BioMed Inc. | Named by the company | 85% |
| POINT Biopharma | Named by the company | 85% |
| Telix | Named by the company | 85% |
| Bayer AG | Named by the company | 85% |
| Novartis AG | Named by the company | 85% |
| RadioMedix, Inc | Named by the company | 85% |
| Ipsen S.A. | Named by the company | 85% |
| Progenics Pharmaceuticals, Inc. | Named by the company | 85% |
| Y-mAbs Therapeutics, Inc. | Named by the company | 85% |
| Clovis Oncology, Inc. | Named by the company | 85% |
| Orano Med | Named by the company | 85% |
| Lantheus | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Qsam Biosciences Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Qsam Biosciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Qsam Biosciences Inc | - | 0 | -1,026,649 |
| Fusion Pharmaceuticals Inc | 1,805 | 33,481 | -3,862,074 |
| Rayzebio Inc | 962 | - | - |
| Actinium Pharmaceuticals Inc | 35 | 58,480 | 1,514,120 |
| PEERS TOTAL | 2,803 | 22,750 | -638,683 |
Qsam Biosciences Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | -100.00 % | - | - | - |
| Operating Margin | - | -126.76 % | - | - | - | - |
| Return on Invested Capital | 51.36 % | 14.92 % | 13.26 % | -957.32 % | 153.69 % | 291.19 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Qsam Biosciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 479.1 points above the industry aggregate.
Weaknesses
No rule matched.
Opportunities
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-86.3% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Qsam Biosciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Qsam Biosciences Inc | 0.57 | 0.75 | - |
| Fusion Pharmaceuticals Inc | 2.07 | 12.24 | 0.20 |
| Rayzebio Inc | - | - | - |
| Actinium Pharmaceuticals Inc | 6.11 | 6.25 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Qsam Biosciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Qsam Biosciences Inc | Q4 2023 | - | - |
| Fusion Pharmaceuticals Inc | Q1 2024 | - | - |
| Rayzebio Inc | Q3 2023 | - | - |
| Actinium Pharmaceuticals Inc | Q2 2026 | - | - |
| PEERS TOTAL | +124,900.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Qsam Biosciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Qsam Biosciences Inc | Q4 2023 | -75.3 % | - |
| Fusion Pharmaceuticals Inc | Q1 2024 | - | +9.1 % |
| Rayzebio Inc | Q3 2023 | - | - |
| Actinium Pharmaceuticals Inc | Q2 2026 | - | - |
Qsam Biosciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Qsam Biosciences Inc | - | - | - |
| Fusion Pharmaceuticals Inc | - | - | - |
| Rayzebio Inc | - | - | - |
| Actinium Pharmaceuticals Inc | 71.73% | 84.38% | 213.46% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Qsam Biosciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Qsam Biosciences Inc | - | - |
| Fusion Pharmaceuticals Inc | - | 1,997.09 |
| Rayzebio Inc | - | - |
| Actinium Pharmaceuticals Inc | 3.50 | 24.06 |
| PEERS AVERAGE | - | 1,184.65 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.